Min Wu, Xiaojiao Li, Deming Yang, Meng Wang, Hong Zhang, Cuiyun Li, Jiajia Mai, Lizhi Yang, Yunpeng Qi, Jin-Chen Yu, Xiaolei Yang, Zhaohe Wang, Cailing Gu, Yanhua Ding
OBJECTIVE: We aimed to evaluate the similarity of BAT2206 to its originator, ustekinumab, including pharmacokinetic profiles, immunogenicity, and safety in healthy Chinese male subjects. METHODS: This was a double-blinded, randomized, single-dose, parallel-group clinical trial, in which 270 healthy male subjects were enrolled to receive a single subcutaneous injection (45 mg) of either BAT2206 or ustekinumab (European Union or USA) at a 1:1:1 ratio. The pairwise pharmacokinetic similarities and the safety and immunogenicity of both drugs were evaluated and compared...
November 22, 2022: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy